Healthcare / Drug Manufacturers - Specialty & GenericTaipei Exchange
$17.25
+0.25 (+1.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $6.3M · quality 43.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$853M
P/E
49.3x
↑EV/EBITDA
21.9x
↑ROE
3.3%
↑Gross Margin
37.1%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-3.7%
FCF CAGR
—
FCF margin
2.8%
FCF / Net income
0.37x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $229.8M · net income $17.4M · FCF $6.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $229.8M | $229.8M | $238.5M | $192.9M | $257.5M |
| Net Income | $17.4M | $17.4M | $8.8M | $-31.8M | $-6.8M |
| EBITDA | $36.7M | $36.7M | $26.3M | $-23.4M | $3.9M |
| EPS | — | — | 0.18 | -0.64 | -0.14 |
| Gross Margin | 37.1% | 37.1% | 35.4% | 17.3% | 25.5% |
| Operating Margin | 5.2% | 5.2% | 1.9% | -21.2% | -5.6% |
| Net Margin | 7.6% | 7.6% | 3.7% | -16.5% | -2.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.06 | 0.02 | 0.04 |
| Current Ratio | 4.55 | 4.55 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $6.3M | $6.3M | $-24.7M | $28.5M | $-39.0M |
| Returns | |||||
| ROE | 3.3% | 3.3% | 1.6% | -6.3% | -1.3% |
| Valuation | |||||
| P/E | 49.29 | 49.29 | 111.67 | — | — |
| EV/EBITDA | 21.94 | 21.94 | 36.65 | — | 192.03 |
| P/B | 1.61 | 1.61 | 1.82 | 1.42 | 1.49 |
| Growth & Yield | |||||
| Revenue Growth | -3.6% | -3.6% | 23.6% | -25.1% | — |
| EPS Growth | — | — | 128.1% | -357.1% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-15.9%
Start / end P/E
n/dx → n/dx
EPS bridge
0.18 → n/d
Residual
-15.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.